{"podcast":{"title":"The Fellow on Call: The Heme/Onc Podcast","slug":"the-fellow-on-call-the-heme-onc-podcast-4669989","podcast_index_feed_id":4669989,"rss_url":"https://www.thefellowoncall.com/tfocpodcast?format=rss","website_url":"https://www.thefellowoncall.com/tfocpodcast/","image_url":"https://images.squarespace-cdn.com/content/v1/61b273ac9be6aa2250498c9e/1641065434990-8BV6L7UFJF4JCCKCY6S1/Untitled+design+%281%29+copy.png?format=1500w","author":"Ronak Mistry","episode_count":164,"summary":"We quickly realized we knew very little about hematology and oncology when we started fellowship. Our goal is to bring you the fundamentals, core concepts and important management approaches in our field, driven by the latest evidence and expert opinion. In each episode, we will provide bite-sized, simplified approaches to common questions in a way that is perfect for anyone interested in hematology and oncology, from students and trainees to advanced practice providers and practicing physicians.","last_synced_at":"2026-06-24T18:17:58.817010+00:00","page_url":"https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989"},"episode":{"title":"Episode 150: Myeloma Series, Pt. 10 - Role of CAR T for relapsed/refractory multiple myeloma (2026)","slug":"episode-150-myeloma-series-pt-10-role-of-car-t-for-relapsed-refractory-multiple-myeloma-2026","published_at":"2026-04-01T08:00:37+00:00","page_url":"https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989/episode-150-myeloma-series-pt-10-role-of-car-t-for-relapsed-refractory-multiple-myeloma-2026","show_page_url":"https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989","url":"https://www.thefellowoncall.com/tfocpodcast/myelomacart","audio_url":"https://static1.squarespace.com/static/61b273ac9be6aa2250498c9e/t/69cbe8a02a6d8d3b1afe7271/1775563507931/The+Fellow+On+Call+-+Myeloma_CAR+T+-+Mix.mp3","summary":"In this week’s episode, we take a practical dive into the relapsed/refractory myeloma space, with a focus on the role of CAR T therapy for relapsed/refractory. In our next episode, we will continue on with a discussion on bispecific agents! This is a conversation that is so important in the current treatment landscape and one that you don’t want to miss. Content: - What are treatment options for patients with relapsed/refractory multiple myeloma (R/R MM)? - What is CAR T therapy? And what role does it play in R/R MM? - What are the available options for CAR T for R/R MM? - What are the toxicity profiles of available agents? - How to choose between the options? ** This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, visit llmcongress.com/podcast ! Be sure to use our special TFOC code TFOC40 to save 40% off registration. ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube","meta_description":"In this week’s episode, we take a practical dive into the relapsed/refractory myeloma space, with a focus on the role of CAR T therapy for relapsed/refrac…","key_points":[],"chapters":[],"topics":[],"duration_seconds":null,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-fellow-on-call-the-heme-onc-podcast-4669989/episodes/episode-150-myeloma-series-pt-10-role-of-car-t-for-relapsed-refractory-multiple-myeloma-2026/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989/episode-150-myeloma-series-pt-10-role-of-car-t-for-relapsed-refractory-multiple-myeloma-2026.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}